Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients: Impact on Insulin Sensitivity, Glucose Tolerance, and Pharmacoeconomics
The purpose of this study is to investigate if co-treatment of acromegalic patients, who beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can be obtained at a neutral cost as compared to SA mono therapy. Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and intramyocellular fat.
Study Arms / Comparison Groups
Description: Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - Age > 18 - Diagnosed with acromegaly - Safe anticonceptive for fertile women - Well controlled on somatostatin analog (a serum IGF-I within normal range a nadir GH < 0.5 µg/l.) Exclusion Criteria: - Pregnancy - Liver disease - Diabetes mellitus type I - Magnetic or electronic implants
18 Years - N/A
Accepts Healthy Volunteers
Jens Otto L. Jørgensen, MD Professor, ,
University of Aarhus
Aarhus University Hospital Skejby
Jens Otto L. Jørgensen, MD Professor, Principal Investigator, Aarhus University Hospital